Executive Summary
- •Shareholders receive $102.50 per share in cash at closing, plus up to $12 per share tied to sales milestones through 2030.
- •The combined operation spans isotope production to diagnostic imaging across more than 70 countries.
- •Lantheus cancels its 2026 guidance and will become a private company when the transaction closes in early 2027.
Community Sentiment
Key Developments & Data
Curium acquires radiopharma rival Lantheus $LNTH in an $8B takeover deal.
Shareholders receive $102.50 per share in cash at closing, plus up to $12 per share tied to sales milestones through 2030.
The combined operation spans isotope production to diagnostic imaging across more than 70 countries.
Lantheus cancels its 2026 guidance and will become a private company when the transaction closes in early 2027.
Zubiqo Intelligence Briefing
Get the unfiltered signal before markets open.
Top tech breakthroughs, venture funding, and market moves—synthesized into a 2-minute morning read. Zero PR fluff.
✓ 100% Free•✓ 1-click unsubscribe•✓ No spam ever
